Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Leukemia, Lymphoma
Interventions
rituximab, cyclophosphamide, pentostatin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Waldenstrom Macroglobulinemia
Interventions
Cyclosporine, Mycophenolate Mofetil, Pentostatin, Therapeutic Allogeneic Lymphocytes
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
4
States / cities
Salt Lake City, Utah • Seattle, Washington
Completed Phase 1Phase 2 Interventional Results available

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

NCT01362790
Conditions
Mesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms
Interventions
Pentostatin, Cyclophosphamide, SS1(dsFv)PE38 - lot 073I0809, SS1(dsFv)PE38 - lot FIL129J01
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, Cyclophosphamide, Lenalidomide, Pentostatin
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
HIV, Hematologic Malignancies
Interventions
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Leukemia, Lymphoma
Interventions
rituximab, pentostatin
Biological · Drug
Lead sponsor
Pharmatech Oncology
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
5
States / cities
Rancho Mirage, California • Redding, California • Clinton, Maryland + 2 more
Conditions
Chronic Lymphocytic Leukemia
Interventions
Nipent, Cytoxan, Rituxan
Drug
Lead sponsor
East Valley Hematology and Oncology Medical Group
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
52
States / cities
Muscle Shoals, Alabama • Burbank, California • Concord, California + 44 more
Conditions
Leukemia, Lymphoma
Interventions
bevacizumab, pegfilgrastim, rituximab, cyclophosphamide, pentostatin
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation, Graft vs Host Disease
Interventions
Alemtuzumab, Sirolimus, Cyclophosphamide, Pentostatin, Radiotherapy, Filgrastim
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Graft Versus Host Disease
Interventions
pentostatin for injection
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
Interventions
75 approved agents, COXEN
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Phase 2 Interventional Results available

A Phase II Study of Umbilical Cord Blood Transplantation

NCT00676806
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia
Interventions
Umbilical Cord Blood After Myeloablative Conditioning, Umbilical Cord Blood After Reduced-Intensity Conditioning
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Graft Versus Host Disease
Interventions
pentostatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
16
States / cities
Lewes, Delaware • Newark, Delaware • Chicago, Illinois + 11 more
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Conditions
Refractory TdT-Positive Leukemia
Interventions
Cordycepin plus Pentostatin
Drug
Lead sponsor
OncoVista, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas
Conditions
Lymphoma
Interventions
Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX)
Procedure · Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
19
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more
Completed Phase 2 Interventional Results available

Phase II Trial of Pentostatin and Targeted Busulfan

NCT00496340
Conditions
Hematologic Malignancies
Interventions
Pentostatin, Busulfan, Rituximab, Allogeneic Hematopoietic Cell Transplant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Hodgkin's Disease, Myelodysplastic Syndrome
Interventions
Methotrexate, Pentostatin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Months to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Terminated Phase 2 Interventional Results available

Alemtuzumab and Pentostatin In T-cell Neoplasms

NCT00453193
Conditions
Lymphoma, Leukemia
Interventions
Pentostatin, Alemtuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Conditions
Graft vs Host Disease, Immune System Disorders
Interventions
Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, Pentostatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Duarte, California • San Diego, California • Stanford, California + 16 more
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Conditions
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
Interventions
Neihulizumab Treatment, Conventional Treatment
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Conditions
Lymphoma
Interventions
Cytoxan, Nipent, Rituxan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Rituximab, Pentostatin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
11
States / cities
Ocoee, Florida • Terre Haute, Indiana • Westminster, Maryland + 8 more